DCM
UTHR icon

Driehaus Capital Management’s United Therapeutics UTHR Stock Holding History

Driehaus Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-45,933
Closed -$12.8M – 440
2022
Q4 		$12.8M Buy
45,933
+8,006
+21% +$2.02M 0.19% 168
2022
Q3 		$7.94M Sell
37,927
-6,841
-15% -$1.53M 0.12% 223
2022
Q2 		$10.5M Buy
+44,768
New +$9.1M 0.17% 190

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Driehaus Capital Management's UTHR Position: Q1 2023 in Review

Driehaus Capital Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 45,933 shares — an estimated $12.8M sold.

Driehaus Capital Management first reported a position in UTHR in Q2 2022 and held it in 3 quarters. The position peaked at $12.8M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Driehaus Capital Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 45,933 United Therapeutics shares in Q1 2023, an estimated $12.8M.
  • Driehaus Capital Management first reported a position in United Therapeutics in Q2 2022 and held it in 3 quarters.
  • Driehaus Capital Management's United Therapeutics position peaked at $12.8M in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Driehaus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.